Navigation Links
Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/15/2009

eceive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
2. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
3. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
9. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 Roche,s Bloodhound technology is on ... in hematology testing, according to Kalorama Information.  The ... of its Bloodhound digital cell imaging technology –as ... hematology analyzer – is notable as a ... current leader CellaVision, but also compete more broadly ...
(Date:7/2/2015)... , June 26, 2015 Research ... "Vitamin D Market by Analog, Application, End-User & by ... to their offering. This market is projected to ... vitamin D in different applications and rising opportunities in countries ... , Italy , and ...
(Date:7/2/2015)... --  EVO Aesthetic Center and Wellness Spa prides ... in Lakeway, Texas and will ... Duality laser. The medical spa is focused on helping ... laser procedures. Their addition of the Astanza Duality will ... their tattoo regret. "The large number of ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... Technologies (OTC Bulletin Board: MCLN ), ... treatment and disposal of medical waste and the ... announced it has partnered with Triumvirate Environmental, a ... engineering and remediation. This agreement will enable Triumvirate ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life sciences company ... results for the third quarter of 2011 after closing of the ... conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and ... the same day at 5:00pm ET (2:00pm PT) and will be ...
Cached Medicine Technology:MedClean Technologies Partners With Triumvirate Environmental 2MedClean Technologies Partners With Triumvirate Environmental 3Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call 2
(Date:7/3/2015)... ... 2015 , ... Scientists at several top US cancer centers believe they now ... Click here to read the complete story , just posted on the Surviving ... Medical Center, and New York University exposed mice with a mutation on the tumor ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief nursing officer recruitment for Jane Phillips Medical Center ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing ... their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, ... news , offering timely lawsuit updates and ovarian cancer warning information. The site is ...
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... Almost every smartphone has an incredibly powerful camera built into it. And when someone ...
(Date:7/3/2015)... ... 03, 2015 , ... The Celebrity Dresses is currently running a promotion through ... celebrities will have the opportunity to get 10% discount on orders that are over ... not have to use coupon codes or remember redemption codes. , There is ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2
... Medical Corporation,(CRM:TSX-V) announced today for the year ended ... its Centers for Colorectal Health compared to,1,699 patient ... Commenting on this achievement, Edward Wright, CEO of ... strong demand for the CRH,O,Regan hemorrhoid banding technology ...
... LENEXA, Kan., Feb. 5 Mediware Information,Systems, Inc. (Nasdaq: ... blood and medication management, reported total revenue for the ... $11,262,000 in the,comparable quarter in fiscal year 2007. Net ... four cents per fully diluted share, compared to net,income ...
... Trade Center had sleeplessness, other problems, study shows , , ... to the World Trade Center terrorist attacks boosted behavioral ... by researchers at the Mount Sinai School of Medicine ... 4 years of age who lived in or attended ...
... New position created to support growth at MDS ... Nordion, a leading provider,of medical isotopes and radiopharmaceuticals, ... position of Senior Vice-President Innovation.,Dr. Covitz will lead ... strategies and identifying new complimentary business,opportunities to better ...
... Access to ... Treatment, NEW YORK, ... finding a cure for breast cancer, the Avon,Foundation will bring together nearly ... Breast Cancer Forum, held February 4-6,in Houston, TX. This year,s Forum, titled ...
... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... it will,host a conference call and live webcast ... 2008 to discuss the Company,s fourth quarter and ... be issued before the U.S.,stock markets open that ...
Cached Medicine News:Health News:CRH Medical Corporation announces substantial increase in patient visits 2Health News:Mediware Reports Second Quarter Fiscal 2008 Results 2Health News:Mediware Reports Second Quarter Fiscal 2008 Results 3Health News:Mediware Reports Second Quarter Fiscal 2008 Results 4Health News:9/11 Exposure Linked to Behavior Trouble in Kids 2Health News:Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation 2Health News:Avon Foundation Brings Together Breast Cancer Experts in Houston to Report Significant New Data 2Health News:Avon Foundation Brings Together Breast Cancer Experts in Houston to Report Significant New Data 3Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2
The rubber, whistle tip catheter with thumb valve has two side eyes to help minimize trauma....
Extra Long Gentle Vactrol® Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
Gentle-Flo® Vactrol® Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
D-Line Coude' Suction Catheter., ,Indications For Usage: , Removal of secretions from respiratory tract , For ease and greater assurance of entering and suctioning the left bronchus ...
Medicine Products: